Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB1 | Q9H4B7 | 3/20 | 0.47 |
| ▸ | TUBB4A | P04350 | 2/20 | 0.47 |
| ▸ | TUBB | P07437 | 2/20 | 0.47 |
| ▸ | TUBA3C | P0DPH7 | 2/20 | 0.47 |
| ▸ | TUBA1B | P68363 | 2/20 | 0.47 |
| ▸ | TUBA4A | P68366 | 2/20 | 0.47 |
| ▸ | TUBB4B | P68371 | 2/20 | 0.47 |
| ▸ | TUBB3 | Q13509 | 2/20 | 0.47 |
| ▸ | TUBB2A | Q13885 | 2/20 | 0.47 |
| ▸ | TUBB8 | Q3ZCM7 | 2/20 | 0.47 |
| ▸ | TUBA3E | Q6PEY2 | 2/20 | 0.47 |
| ▸ | TUBA1A | Q71U36 | 2/20 | 0.47 |
| ▸ | TUBA1C | Q9BQE3 | 2/20 | 0.47 |
| ▸ | TUBB6 | Q9BUF5 | 2/20 | 0.47 |
| ▸ | TUBB2B | Q9BVA1 | 2/20 | 0.47 |
| ▸ | EGFR | P00533 | 3/20 | 0.43 |
| ▸ | PIM1 | P11309 | 3/20 | 0.43 |
| ▸ | PDE9A | O76083 | 4/20 | 0.43 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14916740 | 0.80 | PDE9A (0.65) | EGFRPIM1PDE9APDE1CMEN1 | |
| SCHEMBL5618148 | 0.79 | ALPL (0.45) | MEN1KMT2A | |
| SCHEMBL5618530 | 0.79 | MAPK1 (0.59) | PIM1PDE9APDE1CMEN1KMT2A | |
| SCHEMBL16695703 | 0.73 | KDM4E (0.54) | PIM1MEN1KMT2AIDH1MAPK1 | |
| SCHEMBL5618029 | 0.71 | MAPK1 (0.53) | MEN1KMT2AMAPK1 | |
| SCHEMBL12667306 | 0.70 | KDM4E (0.47) | PIM1PDE9AMEN1KMT2AIDH1 | |
| SCHEMBL5618531 | 0.70 | USP2 (0.41) | MEN1USP2KMT2AMAPK1 | |
| SCHEMBL5618463 | 0.70 | CA1 (0.43) | PDE1C | |
| SCHEMBL3016373 | 0.70 | USP2 (0.52) | EGFRPIM1MEN1USP2KMT2A | |
| SCHEMBL5031028 | 0.69 | TUBB1 (0.78) | TUBB1TUBB4ATUBBTUBA3CTUBA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1392283-A4 | SUBSTITUTED COUMARINS AND QUINOLINES AS CASPASE ACTIVATORS | CYTOVIA INC (US) | 2004-10-20 | — | — | EP | claimed |
| EP-1392283-A1 | SUBSTITUTED COUMARINS AND QUINOLINES AS CASPASES ACTIVATORS | Cytovia, Inc. (US) | 2004-03-03 | — | — | EP | claimed |
| US-20030114485-A1 | Substituted coumarins and quinolines and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. | 2003-06-19 | — | — | US | claimed |
| WO-2002092076-A1 | SUBSTITUTED COUMARINS AND QUINOLINES AS CASPASES ACTIVATORS | CYTOVIA, INC. (US) | 2002-11-21 | — | — | WO | claimed |
| US-7235674-B2 | Substituted coumarins and quinolines and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. (US) | 2007-06-26 | — | — | US | disclosed |
| US-7015328-B2 | Substituted coumarins and quinolines and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. (US) | 2006-03-21 | — | — | US | disclosed |
| US-20050090526-A1 | Substituted coumarins and quinolines and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. (US) | 2005-04-28 | — | — | US | disclosed |
| EP-1392283-A4 | SUBSTITUTED COUMARINS AND QUINOLINES AS CASPASE ACTIVATORS | CYTOVIA INC (US) | 2004-10-20 | — | — | EP | disclosed |
| EP-1392283-A1 | SUBSTITUTED COUMARINS AND QUINOLINES AS CASPASES ACTIVATORS | Cytovia, Inc. (US) | 2004-03-03 | — | — | EP | disclosed |
| US-20030114485-A1 | Substituted coumarins and quinolines and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. | 2003-06-19 | — | — | US | disclosed |
| WO-2002092076-A1 | SUBSTITUTED COUMARINS AND QUINOLINES AS CASPASES ACTIVATORS | CYTOVIA, INC. (US) | 2002-11-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030114485-A1 | Substituted coumarins and quinolines and analogs as activators of caspases and inducers of apoptosis and the use thereof | CASP7, CASP1, CASP5 | TUBB1 1383/4885TUBB4A 1497/4885TUBB 1719/4885 |
| US-20050090526-A1 | Substituted coumarins and quinolines and analogs as activators of caspases and inducers of apoptosis and the use thereof | CASP7, CASP5, CASP14 | TUBB1 1609/4885TUBB4A 1400/4885TUBB 1625/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.